Racura Oncology Ltd (ASX:RAC) Share Price

Company Profile

Business description
Racura Oncology Ltdis a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Racura's primary asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that functions by binding to G4-DNA and RNA, resulting to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent researchs made by the company have enabled composition of matter IP filings that provide for 20 years of patent protection over RCDS1. Racura is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications.
Contact
1 Macquarie Place
Level 36
Gateway
SydneyNSW2000
AUS
T: +61 280513043
https://www.racuraoncology.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees

Recommended

Amid robust demand for semis, watch for any impact of in-house built chips and whether the supply chain is on track.

Brian Colello, CPA | 12 May 2026

Interest rates are driving a spike in property listings.

Roy Van Keulen | 12 May 2026

With uncertainty regarding its total addressable market and competitive threats, here’s what we think of Palantir stock.

Mark Giarelli | 12 May 2026

Index	Last price	Change	% Change
All Ordinaries	8,890.90	17.90	0.20%
CAC 40	7,979.92	76.46	-0.95%
DAX 40	23,954.93	395.35	-1.62%
Dow JONES (US)	49,760.56	56.09	0.11%
FTSE 100	10,265.32	4.11	-0.04%
HKSE	26,280.12	67.79	-0.26%
NASDAQ	26,088.20	185.92	-0.71%
Nikkei 225	62,930.20	187.63	0.30%
NZX 50 Index	13,024.37	55.96	-0.43%
S&P 500	7,400.96	11.88	-0.16%
S&P/ASX 200	8,644.20	13.20	0.15%
SSE Composite Index	4,213.01	1.48	-0.04%